ArticleCurrent molecular biology reports2016
Systemic Control of Bone Homeostasis by FGF23 Signaling.
Article in Current molecular biology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Effect of Cholecalciferol therapy on serum FGFJournal of endocrinological investigation · 2018Trial
- Potential value of vitamin D as adjunctive therapy in osteoarticular tuberculosis: a comprehensive review.Infection · 2026Review
- Cereblon regulates the production of hepatic fibroblast growth factor 23 in diabetes.BMB reports · 2024Article
- Impact of deoxynivalenol in a calcium depletion and repletion nutritional strategy in piglets.Journal of animal science · 2024Article
- X-Linked Familial Hypophosphatemia: A Case Report of 27-Year Old Male and Review of Literature.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2023Review
- Regulation of the Osteocyte Secretome with Aging and Disease.Calcified tissue international · 2023Review
- Article
- Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.Physiological reports · 2022Article
- Vitamin D and Phosphate Interactions in Health and Disease.Advances in experimental medicine and biology · 2022Article
- Regulation of FGF23: Beyond Bone.Current osteoporosis reports · 2021Review
- Review
- Isolated hypophosphataemia as an early marker of primary hyperparathyroidism.Endocrinology, diabetes & metabolism case reports · 2021Article
- FGF/FGFR signaling in health and disease.Signal transduction and targeted therapy · 2020Review
- Drug-Induced Hypophosphatemia: Current Insights.Drug safety · 2020Review
- Molecular signaling in bone cells: Regulation of cell differentiation and survival.Advances in protein chemistry and structural biology · 2019Review
- Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters.Pflugers Archiv : European journal of physiology · 2019Review
- Biology and Mechanisms of Action of the Vitamin D Hormone.Endocrinology and metabolism clinics of North America · 2017Review
- The Role of the Osteocyte in Bone and Nonbone Disease.Endocrinology and metabolism clinics of North America · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The regulation of phosphate metabolism as an influence on bone homeostasis is profound. Recent advances in understanding the systemic control of Fibroblast growth factor-23 (FGF23) has uncovered novel effectors of endocrine feedback loops for calcium, phosphate, and vitamin D balance that interact with 'traditional' feedback loops for mineral metabolism. Not only are these findings re-shaping research studying phosphate handling and skeletal interactions, they have provided new therapeutic interventions. Emerging data support that the control of FGF23 production in bone and its circulating concentrations is a multi-layered process, with some influences affecting FGF23 transcription and some post-translational modification of the secreted, bioactive protein. Additionally, the actions of FGF23 on its target tissues via its co-receptor αKlotho, are subject to regulatory events just coming to light. The recent findings of systemic influences on circulating FGF23 and the downstream manifestations on bone homeostasis will be reviewed herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.